Mark Napier - Concepedia

Author

Mark Napier

Council for Scientific and Industrial Research ORCID

Also Known As

Berrisford, Stephen, M Napier, M P Napier, M. Napier, M.P. NAPIER, M.P. Napier, MARK NAPIER, MP Napier, Mark Napier, Napier, M

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Council for Scientific and Industrial Research University College London The Royal Free Hospital Roland Hill (United Kingdom)Newcastle University

About

Mark Napier is an author at Council for Scientific and Industrial Research specializing in social sciences, sociology, and african development.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	522
2	Business	1	1	88
3	Health Sciences	1	1	241
4	Law	1	1	11
5	Management	1	1	88

Mark Napier

Publications

928

Citations

H-Index

Page 1

	Year	Citations
Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial library Richard H. J. Beǵent, Marlies J. Verhaar, Kerry Chester, Nature Medicine ImmunologyImmunotherapeuticsImmunotherapyTumor ImmunologyTumor Immunity	1996	241
Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Mark Napier, Shruti Sharma, Caroline J. Springer, PubMed GlycobiologyPathologyBiological TherapyTumor BiologyColorectal Carcinoma	2000	129
Making a Living in African Cities: The Role of Home-based Enterprises in Accra and Pretoria Katherine V. Gough, A. Graham Tipple, Mark Napier International Planning Studies Economic DevelopmentDevelopment EconomicsProperty CrimeSocial SciencesManagement	2003	88
Waiting for a house or building your own? Reconsidering state provision, aided and unaided self-help in South Africa Karina Landman, Mark Napier Habitat International African Social ChangePublic PolicyCommunity DevelopmentUnaided Self-helpDevelopment Aid	2010	81
Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial Janet Martin, Stephen M. Stribbling, Grace K. Poon, Cancer Chemotherapy and Pharmacology Plasma LevelsMedicineImmunologyAntibody EngineeringPharmacotherapy	1997	79
Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non–Small-Cell Lung Cancer: ERCC1 Trial (ET) Siow Ming Lee, Mary Falzon, Fiona Blackhall, Journal of Clinical Oncology	2017	60
Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer Martin Hoyle, Jaime Peters, Louise Crathorne, Value in Health Surgical OncologyGastrointestinal OncologyMedicinePathologyColorectal Cancer	2013	44
Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study Joanne L. Casey, Mark Napier, David J. King, British Journal of Cancer	2002	43
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England Irina A. Tikhonova, Nicola Huxley, Tristan Snowsill, PharmacoEconomics Surgical OncologyGastrointestinal OncologyMedicinePathologyEconomic Analysis	2018	29
Housing interventions for preventing malaria Joanna Furnival-Adams, Evelyn A Olanga, Mark Napier, Cochrane Database of Systematic Reviews	2019	19

Page 1